Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
Adv Rheumatol ; 60: 07, 2020. tab
Article in English | LILACS | ID: biblio-1088641

ABSTRACT

Abstract Background: Fabry disease (FD) is an X-linked lysosomal disorder due to mutations in the GLA gene resulting in defective enzyme alpha-galactosidase A. FD patients are frequently misdiagnosed, commonly for rheumatic diseases. Determining pathogenicity of a mutation depends of in silico predictions but mostly on available clinical information and interpretation may change in light of evolving knowledge. Similar signs and symptoms in carriers of GLA gene genetic variants of unknown significance or of benign variants may hamper diagnosis. This study reviews rheumatic and immune-mediated manifestations in a cohort of Brazilian FD patients with classic mutations and also in subjects with GLA gene A143T and R118C mutations. Misdiagnoses, time to correct diagnosis or determination of GLA gene status, time to treatment initiation and reasons for treatment prescription in A143T and R118C subjects are reviewed. Methods: Genotype confirmed classic FD patients (n = 37) and subjects with GLA gene mutations A143T and R118C (n = 19) were referred for assessment. Subjects with R118C and A143T mutations had been previously identified during screening procedures at hemodialysis units. All patients were interviewed and examined by a rheumatologist with previous knowledge of disease and/or mutation status. A structured tool developed by the authors was used to cover all aspects of FD and of common rheumatic conditions. All available laboratory and imaging data were reviewed. Results: Thirty-seven consecutive FD patients were interviewed - 16 male / 21 female (mean age: 43.1 years) and 19 consecutive subjects with GLA gene mutations R118C and A143T were evaluated - 8 male / 11 female (mean age: 39.6 years); 15 [R118C] / 4 [A143T]. Misdiagnosis in FD patients occurred in 11 males (68.8%) and 13 females (61.9%) of which 10 males and 9 females were previously diagnosed with one or more rheumatic conditions, most frequently rheumatic fever or "rheumatism" (unspecified rheumatic disorder). Median time for diagnosis after symptom onset was 16 years (range, 0-52 years). Twenty-two patients were treated with enzyme replacement therapy (ERT) - 13 male and 9 female. Median time to ERT initiation after FD diagnosis was 0.5 years (range, 0-15 years). Rheumatic manifestations occurred in 68.4% of R118C and A143T subjects. Two subjects had been prescribed ERT because of renal disease [R118C] and neuropsychiatric symptoms [A143T]. Conclusion: Misdiagnoses occurred in 64.8% of FD patients, most frequently for rheumatic conditions. Median time for correct diagnosis was 16 years. Rheumatic manifestations are also frequent in subjects with GLA gene R118C and A143T mutations. These results reinforce the need to raise awareness and increase knowledge about Fabry disease among physicians, notably rheumatologists, who definitely have a role in identifying patients and determining disease burden. Decision to start treatment should consider expert opinion and follow local guidelines.(AU)


Subject(s)
Humans , Fabry Disease/diagnosis , Diagnostic Errors , Brazil , Cohort Studies , Delayed Diagnosis
3.
Arq. bras. cardiol ; 113(1): 77-84, July 2019. tab, graf
Article in English | LILACS | ID: biblio-1011241

ABSTRACT

Abstract Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the alpha galactosidase A gene (GLA) that lead to the enzymatic deficiency of alpha galactosidase (α-Gal A), resulting in the accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), causing multiple organ dysfunctions. Objective: To perform GLA gene screening in a group of patients with echocardiographic diagnosis of hypertrophic cardiomyopathy (HCM). Methods: a cross-sectional study was conducted with HCM patients from a university hospital. Patients with coronary artery disease and valvulopathies were excluded. Mutation analysis of the GLA gene was performed. In male subjects, the analysis was performed after evidence of low α-Gal A activity. Results: 60 patients with echocardiographic diagnosis of HCM were included. Age ranged from 12 to 85 years and 60% were women. Mean myocardial fibrosis percentage on MRI was 10.7 ± 13.1% and mean ventricular thickness was18.7 ± 6.7 mm. Four patients had the following GLA gene mutations: c.967C>A (p.Pro323Thr), not yet described in the literature; c.937G>T (p.Asp313Tyr); and c.352C>T (p.Arg118Cys). All patients had normal levels of lyso-Gb3 and non-ischemic myocardial fibrosis on magnetic resonance imaging; one patient had proteinuria and one patient had ventricular tachycardia. Conclusion: in this study, the frequency of mutation in the GLA gene in patients with HCM was 6.7%. A novel mutation in exon 6 of the GLA gene, c.967C>A (p.Pro323Thr), was identified. Patients with HCM may have GLA mutations and FD should be ruled out. Plasma (lyso-Gb3) levels do not seem to be sufficient to attain a diagnosis and organ biopsy should be considered.


Resumo Fundamento: A doença de Fabry (DF) é uma doença de armazenamento lisossômico ligada ao cromossomo X, devido a mutações no gene da alfa galactosidase A (GLA), levando a deficiência enzimática de alfa-galactosidase (α-Gal A) e acúmulo de globotriaosilceramida (Gb3) e globotriaosilsulfingosina (liso-Gb3), causando disfunção de múltiplos órgãos. Objetivo: realizar a triagem do gene GLA em um grupo de pacientes com diagnóstico ecocardiográfico de cardiomiopatia hipertrófica (CMH). Métodos: estudo transversal realizado com pacientes com CMH em um hospital universitário. Pacientes com doença arterial coronariana e valvopatias foram excluídos. Foi realizada análise de mutação do gene GLA. Em indivíduos do sexo masculino, a análise foi realizada após evidência de baixa atividade de α-Gal A. Resultados: Foram incluídos 60 pacientes com diagnostico ecocardiográfico de CMH. A idade variou de 12 a 85 anos e 60% eram mulheres. O percentual médio de fibrose miocárdica na RM foi 10,7 ± 13,1% e a espessura ventricular média foi 18,7 ± 6,7 mm. Quatro pacientes tinham as seguintes mutações do GLA: c.967C>A (p.Pro323Thr), ainda não descrita na literatura; c.937G>T (p.Asp313Tyr); e c.352C>T (p.Arg118Cys). Todos os pacientes apresentavam níveis normais de liso-Gb3 e fibrose miocárdica não isquêmica na ressonância magnética; um paciente apresentou proteinúria; um paciente apresentou taquicardia ventricular. Conclusão: Neste estudo, a frequência de mutação no gene GLA em pacientes com CMH foi 6,7%. Uma nova mutação no exon 6 do gene GLA, c.967C>A (p.Pro323Thr), foi identificada. Pacientes com CMH podem ter mutações do GLA e a DF deve ser excluída. Os níveis plasmáticos de (liso-Gb3) não parecem ser suficientes para fazer um diagnóstico e biópsia de órgãos deve ser considerada.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Cardiomyopathy, Hypertrophic/genetics , alpha-Galactosidase/genetics , Mutation/genetics , Cardiomyopathy, Hypertrophic/etiology , Cardiomyopathy, Hypertrophic/diagnostic imaging , Magnetic Resonance Imaging , Echocardiography , Genetic Testing , Cross-Sectional Studies , Fabry Disease/complications , Fabry Disease/diagnosis
4.
Rev. méd. Chile ; 146(9): 1079-1084, set. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-978801

ABSTRACT

Fabry's disease is an X-linked multisistemic lisosomal storage disorder caused by deficiency or absence in α-Galatosidase A. Symptoms develop early in childhood with small fiber neuropathy, autonomic disorders and skin lesions (angiokeratomas). More severe in males, patients develop over years heart disease (hypertrophic cardiomyopathy, bradycardia), proteinuria, renal failure, transient ischemic attacks and stroke, associated with decreased life expectancy. We report five patients with Fabry's disease aged between 21 to 56 years and with family history. Neuropathic symptoms are described and neurophysiological testing findings of nerve conduction studies, quantitative sensory testing, autonomic testing and sympathetic skin response are presented.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Fabry Disease/diagnosis , Carbamazepine/therapeutic use , Sensitivity and Specificity , Fabry Disease/drug therapy , Peripheral Nervous System Diseases/diagnosis , Analgesics, Non-Narcotic/therapeutic use , Somatosensory Disorders/diagnosis , Enzyme Replacement Therapy
5.
An. bras. dermatol ; 93(3): 426-428, May-June 2018. graf
Article in English | LILACS | ID: biblio-949873

ABSTRACT

Abstract: Fabry disease is a rare lysosomal storage disorder, inherited in an X-linked manner. It is characterized by the deficiency of the enzyme alpha-galactosidase, leading to a buildup of glycosphingolipids in the cells. Angiokeratoma is one of the cutaneous manifestations of this condition, and it helps making the diagnosis. The typical site involves the genital area in men and lumbosacral, buttocks and trunk region in both sexes. We report a case of genital angiokeratoma in a woman with Fabry disease. The diagnosis is through molecular analysis and, when made early, starting treatment reduces the morbidity and mortality of the disease. Thus, the dermatologist has an important role in the identification of angiokeratoma as a cutaneous marker, and the knowledge of its different presentations is essential for the early diagnosis and management of Fabry disease.


Subject(s)
Humans , Female , Middle Aged , Skin Neoplasms/diagnosis , Vulvar Neoplasms/diagnosis , Fabry Disease/diagnosis , Angiokeratoma/diagnosis , Physician's Role , Skin Neoplasms/pathology , Vulvar Neoplasms/pathology , Diagnosis, Differential , Enzyme Replacement Therapy , Dermatologists , Angiokeratoma/pathology
6.
J. bras. nefrol ; 39(3): 333-336, July-Sept. 2017. tab
Article in English | LILACS | ID: biblio-893763

ABSTRACT

Abstract Fabry disease is an X-linked lysosomal storage disease due to alpha-galactosidase A (α-Gal A) deficient activity which leads to the accumulation of glucoesphingolipids, such as globotriaosilceramide. There are over 700 known mutations of the enzyme gene, and most of them cause Fabry Disease. This case report describes a hemodialysis patient with a rare and controversial GLA gene mutation, the D313Y. The medecial investigation confirmed that D313Y is an alpha-galactosidase A sequence variant that causes pseudo deficient enzyme activity in plasma but not Fabry disease. Thus, clinical symptoms that prompted Fabry disease investigation could not be attributable to Fabry disease and therefore enzyme replacement therapy was not indicated.


Resumo Doença de Fabry (DF) é uma doença de depósito lisossômico ligada ao cromossomo X, causada pela deficiência da enzima alfa-galactosidase A (α-Gal A) que leva ao acúmulo de glicoesfingolipídeos, principalmente globotriaosilceramide. Existem mais de 700 mutações conhecidas do gene da enzima, a maioria delas são causadoras de DF. Este relato de caso descreve sobre um paciente em hemodiálise com uma mutação do gene GLA rara e controversa, a D313Y. A investigação médica confirmou que D313Y é uma variante que leva à pseudodeficiência plasmática da enzima, mas não ocasiona DF. Assim, os sintomas clínicos que induziram a investigação da doença não devem ser atribuídos à DF e, portanto, não foi indicada a terapia de reposição enzimática.


Subject(s)
Humans , Male , Adult , Fabry Disease/diagnosis , Fabry Disease/enzymology , alpha-Galactosidase/physiology , alpha-Galactosidase/genetics , Isoenzymes/physiology , Isoenzymes/genetics , Mutation
7.
J. bras. nefrol ; 38(2): 245-254, graf
Article in Portuguese | LILACS | ID: lil-787869

ABSTRACT

Resumo Todas as células do corpo humano apresentam acúmulo de globotriaosilceramida (Gb3) na doença de Fabry devido à mutação que ocorre no gene da enzima α-galactosidase A. Trata-se de uma doença ligada ao sexo. Os achados clínicos são: angioqueratomas cutâneos; acroparestesias e acidentes vasculares encefálicos precoces; sudorese diminuída e intolerância ao calor; alterações oculares; hipertrofia miocárdica, arritmias; alterações gastrointestinais e renais. O envolvimento renal ocorre devido ao acúmulo do Gb3 em todos os tipos de células renais. Portanto, os pacientes podem apresentar distúrbios das funções glomerulares e tubulares. Os podócitos são particularmente acometidos, com apagamento dos pedicélios e desenvolvimento de proteinúria. O diagnóstico é feito por meio da detecção de reduzida atividade plasmática ou leucocitária da α-galactosidase e pela detecção da mutação do gene da α-galactosidase. O tratamento com reposição enzimática contribui para o retardo da progressão da doença renal, principalmente se instituído precocemente.


Abstract Every cell in the human body has globotriaosylceramide accumulation (Gb3) in Fabry disease due to the mutation in gene of the enzyme α-galactosidase A. It is a disease linked to sex. The main clinical features are: cutaneous angiokeratomas; acroparestesias and early strokes; decreased sweating and heat intolerance; ocular changes; myocardial hypertrophy, arrhythmias; gastrointestinal disorders and renal involvement. Renal involvement occurs due to Gb3 accumulation in all types of renal cells. Therefore, patients may present glomerular and tubular function disorders. Podocytes are particularly affected, with pedicels effacement and development of proteinuria. The diagnosis is made by detection of reduced plasma or leukocyte α-galactosidase activity and genetic study for detecting the α-galactosidase gene mutation. Treatment with enzyme replacement contributes to delay the progression of kidney disease, especially if initiated early.


Subject(s)
Humans , Fabry Disease/complications , Kidney Diseases/etiology , Biopsy , Fabry Disease/diagnosis , Fabry Disease/therapy , Kidney Diseases/pathology
8.
Acta bioquím. clín. latinoam ; 50(1): 17-25, mar. 2016. ilus, graf, tab
Article in Spanish | LILACS | ID: biblio-837587

ABSTRACT

La enfermedad de Fabry es una patología genética debida a la deficiencia de la enzima α-galactosidasa A. En la Facultad de Ciencias Exactas de la Universidad Nacional de La Plata se implementaron estudios de diagnóstico de enfermedades lisosomales y se comenzó por la Enfermedad de Fabry. Se llevó a cabo un estudio dirigido a la detección de pacientes Fabry no diagnosticados mediante un enfoque biomédico multidisciplinario. Se realizó una evaluación nefrológica de los pacientes argentinos detectados y un análisis de sus manifestaciones clínicas durante el tratamiento de reemplazo enzimático. Los pacientes tratados con agalsidasa alfa recibieron sus primeras infusiones en centros médicos y luego la infusión fue domiciliaria. Los datos de los pacientes argentinos fueron registrados en la base de datos FOS, un registro internacional multicéntrico. Los estudios de investigación básica realizados mostraron la existencia de un estado proinflamatorio en células de pacientes Fabry, lo cual podría explicar parte de su fisiopatología. El abordaje de las enfermedades poco frecuentes no es sencillo, sobre todo ante la falta de políticas sanitarias de parte del Estado. Este trabajo permitió lograr múltiples objetivos: la difusión de la Enfermedad de Fabry en Argentina, mayor sospecha clínica en la comunidad médica y mejor accesibilidad al diagnóstico, seguimiento y tratamiento para los pacientes.


A Fabry disease is an X-linked lysosomal disorder that results from a deficiency of the lysosomal enzyme alpha-galactosidase A. The implementation of biochemical and genetic tests for lysosomal diseases was carried out in our institution, the School of Exact Sciences, Universidad Nacional de La Plata. A successful approach for the detection of Fabry patients in Argentina was developed by constitutingan interdisciplinary group of professionals. A nephrological assessment of the Argentine patients detected was made andthe clinical manifestations of Fabry patients were analysed and recorded in a FOS international registry. Patients received their enzyme replacement therapy, and the infusion was offered at home. Research studies carried out by our group showed the existence of a proinflammatory state in cells from Fabry patients, which could be related to the pathophysiology. Approaching rare diseases is not easy, especially when there is a lack of State health care policies. This work led us to achieve objectives such as disseminate knowledge about the disease in our country, enhance clinical suspicion and improve accessibility to diagnosis and treatment for patients.


Doença de Fabry é uma doença genética que resulta da deficiência da enzima α-galactosidase A. Na Faculdade de Ciências Exatas da Universidade Nacional de La Plata foram implementados estudos de diagnóstico de doenças lisossomais e a primeira foi a Doença de Fabry. Realizou-se um estudo orientado à detecção de pacientes Fabry não diagnosticados mediante uma abordagem biomédica multidisciplinar. Foi feita uma avaliação nefrológica dos pacientes argentinos detectados e uma análise de suas manifestações clínicas durante o tratamento de reposição enzimática. Os pacientes tratados com agalsidase alfa receberam suas primeiras infusões em centros médicos, e depois a infusão foi domiciliar. Os dados dos pacientes argentinos se registraram na base de dados FOS, um registro internacional multicêntrico. Estudos de pesquisa básica realizados mostraram a existência de um estado pró-inflamatório em células de pacientes Fabry, o que poderia explicar parte de sua fisiopatologia. A abordagem das doenças pouco frequentes não é simples, principalmente diante da falta de políticas sanitárias de parte do Estado. Este trabalho permitiu alcançar objetivos múltiplos: a difusão da Doença de Fabry na Argentina, maior suspeita clínica na comunidade médica, e melhor acessibilidade ao diagnóstico, seguimento e tratamento para os pacientes.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Fabry Disease , Fabry Disease/diagnosis , Genetic Diseases, X-Linked , Argentina , Clinical Laboratory Techniques , Heterozygote , Lysosomes
9.
Rev. Soc. Bras. Clín. Méd ; 13(3)dez. 2015. ilus
Article in Portuguese | LILACS | ID: lil-774724

ABSTRACT

A doença de Fabry é uma enfermidade genética ligada ao cromossomoX e de caráter progressivo, causada pela deficiênciaparcial ou total da enzima alfa galactosidase A (?-Gal A). Habitualmenteo diagnóstico é tardio em função das complicaçõespatológicas provocadas pela deficiência da enzima. OBJETIVO:Neste estudo, descrevemos os aspectos clínicos de um caso familiaratravés do acompanhamento ao longo de 3 anos, duranteo tratamentopela reposição enzimática. MÉTODOS: O métodoadotado foi indutivo, relacionado ao estudo de caso familiarde pacientes com doença de Fabry. Quanto à natureza das informações,a pesquisafoi qualitativa, utilizando-se, quanto aoseu objetivo, à pesquisa exploratória. Com relação as fonte deinformação e procedimento de coleta, a pesquisa caracteriza-secomo sendo bibliográfica e documental. A amostra foi compostapor três pacientesque realizamacompanhamento quinzenalpara aplicação de terapia de reposição enzimática. O critério deinclusão para a pesquisa partiu do pressuposto de se considerarque a doença de Fabry é uma afecção rara e que a família estudadacontempla com riqueza manifestações clínicas, capazesde caracterizar a doença de Fabry. RESULTADOS: Os principaissintomas clínicos relatados pelos pacientes foram: crisede dor generalizada, fadiga, acroparestesia, febre, mialgia, dorabdominal, hipohidrose, intolerância ao frio, calor e ao exercíciofísico. Esses sintomas segundo os pacientes surgiram nainfância e foram amenizados após o uso da terapia de reposiçãoenzimática, propiciando uma melhor qualidade de vida para osmesmos. Também, se observou sinais específicos desta patologianos pacientes, como córnea verticillata e angioqueratoma. Atravésda genotipagem se verificou a semelhança da mutação entre os pacientes do estudo, demonstrando padrão típico de herançarecessiva ligada ao cromossomo X. CONCLUSÃO: Os pacientesdeste estudo apresentaram quadro clínico semelhante,sendoque a sintomatologia iniciou na infância. Córnea verticillata eangioqueratoma umbilical foram sinais encontrados nos pacientes do sexo masculino e são considerados manifestações clínicas frequentes desta patologia. A herança encontrada nesta amostra tem um padrão típico de herança recessiva ligada ao cromossomo X. Desta forma, apesar de ser uma afecção rara na população em geral, o diagnóstico precoce e a terapia de reposição enzimática permitem a evolução clínica favorável e a melhoria da qualidade de vida do paciente.(AU)


Fabry disease is a genetic disorder linked to the X chromosomeand progressive, caused by partial or total deficiency of alphagalactosidase A (?-Gal A). Usually the diagnosis is delayed dueto the pathological complications caused by deficiency of theenzyme. OBJECTIVE: In this study, we describe the clinicalaspects of a family case by monitoring for over three years,during the treatment by enzyme replacement. METHODS:The method adopted was inductive, related to the study of afamily case with patients with Fabry disease. About the nature ofthe information, the research was qualitative, using, as its goal,the exploratory research. Regarding the source of informationand collection procedure, the research is characterized asbibliographical and documentary. The sample was composed ofthree patients submitted to biweekly monitoring for applicationof enzyme replacement therapy. The inclusion criterion forthe research assumed to consider that Fabry disease is a raredisease and that the studied family contemplates with wealththe clinical manifestations, able to characterize the Fabrydisease. RESULTS: The main clinical symptoms related bypatients were: generalized pain crisis, fatigue, acroparesthesia,fever, myalgia, abdominal pain, hypohidrosis, intolerance tocold, heat and exercise. These symptoms according to patientsemerged in childhood and were alleviated after the use ofenzyme replacement therapy, providing a better quality of lifefor them. Also, we found specific signs of this disease in patients,as verticillata cornea and angiokeratoma. By genotyping, it wasfound the similarity of the mutation among patients in thestudy, showing typical pattern of recessive inheritance linkedto chromosome X. CONCLUSION: The patients in this study showed similar clinical condition, and the symptoms began inchildhood. Verticillata cornea and umbilical angiokeratomasigns were found in male patients and are considered commonclinical manifestations of this pathology. The heritage found inthis sample has a typical pattern of recessive inheritance linkedto chromosome X. Thus, despite being a rare disease in generalpopulation, early diagnosis and enzyme replacement therapyallow favorable clinical evolution and improved patient qualityof life.(AU)


Subject(s)
Humans , Glucan 1,4-alpha-Glucosidase/therapeutic use , Fabry Disease/diagnosis , Enzyme Replacement Therapy , Angiokeratoma , Clinical Enzyme Tests/instrumentation , Genotyping Techniques/instrumentation
10.
ABC., imagem cardiovasc ; 28(3): 175-184, jul.-set. 2015. ilus, graf
Article in Portuguese | LILACS | ID: lil-764283

ABSTRACT

A ressonância magnética cardiovascular tem uma de suas maiores vantagens na caracterização tecidual de diversas estruturas e doenças cardíacas. Nos últimos anos, essa caracterização deixou de ser apenas qualitativa e passou a ser medida de forma objetiva através de mapas paramétricos dos valores de T1, T2 e T2*. Esses mapas permitiram a mensuração de áreas de edema, inflamação, cicatrizes e, sobretudo, da avaliação de alterações miocárdicas sistêmicas que ocorrem no espaço extracelular cuja identificação não era possível até então por outras técnicas de ressonância ou demais métodos de imagem. As aplicações clínicas que se seguiram a esse desenvolvimento técnico foram extremamente rápidas e ampliaram de forma significativa a capacidade diagnóstica e prognóstica do cardiologista clínico em diversas doenças. Nesta atualização, buscou-se revisar toda a parte técnica do exame com foco sobretudo nas implicações práticas de utilização do método, destacando-se quais tipos de sequência utilizar, quais os parâmetros críticos e como reportar os valores gerados de T1 nativo, T2, T1 pós-contraste e volume extracelular. Na parte clínica, tentamos identificar e hierarquizar de forma prática em quais doenças os mapas paramétricos estão mais bem estabelecidos e como aplicar esse conhecimento para decisões clínicas. Esse campo em particular é sujeito a mudanças rápidas e constantes e o número de publicações a respeito segue em crescimento exponencial nos últimos anos. Esta revisão tenta fazer uma ponderação das evidências atuais para que se possa continuar seguindo a evolução do método de maneira sólida e consciente. A ressonância magnética cardiovascular (RMC) é um exame cada vez mais empregado na rotina clínica do cardiologista, sendo suas indicações bastante amplas tanto para avaliação morfológica e funcional do coração quanto para pesquisa de isquemia e cicatrizes miocárdicas¹. A caracterização e...


Subject(s)
Humans , Heart/physiopathology , Magnetic Resonance Spectroscopy , Magnetic Resonance Imaging/trends , Amyloidosis/complications , Amyloidosis/diagnosis , Cardiomyopathies/physiopathology , Fabry Disease/complications , Fabry Disease/diagnosis , Heart Rate
11.
Indian J Dermatol Venereol Leprol ; 2015 Jan-Fer ; 81 (1): 46-49
Article in English | IMSEAR | ID: sea-155005

ABSTRACT

Angiokeratoma corporis diffusum is the cutaneous hallmark of several rare inherited lysosomal diseases associated with specific enzyme deficiencies in the metabolism of glycoproteins, most notably Fabry disease. These defects result in many systemic manifestations. Here, we report a rare familial case of angiokeratoma corporis diffusum that developed at puberty with no major systemic manifestations and no underlying enzyme defect or gene mutation. Familial angiokeratoma corporis diffusum without identified enzyme defect appears to be a distinct clinical entity with a benign course.


Subject(s)
Adult , Fabry Disease/diagnosis , Fabry Disease/epidemiology , Fabry Disease/ethnology , Fabry Disease/etiology , Fabry Disease/genetics , Fabry Disease/pathology , Family , Female , Humans , Puberty , Taiwan
12.
Medicina (B.Aires) ; 73(5): 482-494, oct. 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-708540

ABSTRACT

La enfermedad de Fabry es un trastorno de almacenamiento lisosomal hereditario ligado al cromosoma X, ocasionado por el déficit de la enzima alfa galactosidasa A. El conocimiento sobre esta patología, y en particular su manejo médico, ha progresado notablemente en la última década, incluyendo el desarrollo de su tratamiento específico. La presente guía fue desarrollada por profesionales médicos de diversas especialidades involucrados en la atención de pacientes con enfermedad de Fabry. La discusión y análisis de las evidencias científicas disponibles, sumado a la experiencia de cada uno de los participantes, ha permitido desarrollar los conceptos vertidos en esta guía con el objetivo de brindar una herramienta útil para todos los profesionales que asisten a pacientes con enfermedad de Fabry.


Fabry disease is an X-linked hereditary lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A. Knowledge about this disease, and its medical management, has made remarkable progress in the last decade, including the development of its specific treatment. This guide was developed by medical professionals from various specialties involved in the care of patients with Fabry disease. The discussion and analysis of the available scientific evidence, coupled with the experience of each of the participants, has allowed us to develop the concepts included in this guide in order to provide a useful tool for all professionals who care for patients with Fabry disease.


Subject(s)
Female , Humans , Male , Fabry Disease/diagnosis , Fabry Disease/therapy , Age Factors , Enzyme Replacement Therapy , Fabry Disease/physiopathology , Time Factors
13.
Rev. chil. neuro-psiquiatr ; 50(3): 191-201, set. 2012. tab
Article in Spanish | LILACS | ID: lil-656336

ABSTRACT

Fabry's disease is an X-linked recessive inborn error of metabolism of glycosphingolipids, caused by the deficiency of the lisosomal enzyme alpha-galactosidase. It is a rare disease with an estimated incidence rate of approximately 1:80.000 to 1:117,000 births in the general population. Recently, the growing knowledge about this disease has permitted the development of enzyme replacement therapy, which has modified the prognosis and quality of life of these patients. In Chile, the real incidence is unknown, but the increase in the number of patients diagnosed during the last five years, mainly in the north of the country. This guide was prepared with the intention of establishing a consensus for the diagnosis, treatment and monitoring of the patients with Fabry disease based on the present available scientific evidence.


La enfermedad de Fabry es un error innato del catabolismo de los glucoesfingolipidos, de herencia recesiva ligada al cromosoma X, causado por la deficiencia de la enzima lisosomal alfa-galactosidasa A (alfa-gal A). Es un defecto poco frecuente, con una incidencia estimada de 1:80.000 a 1:117.000, entre la población general. Recientemente, el creciente conocimiento acerca de esta enfermedad, ha permitido el desarrollo de la terapia de reemplazo enzimático, la cual ha modificado el pronóstico y calidad de vida de los pacientes. En Chile, se desconoce la incidencia real, pero el aumento del número de pacientes diagnosticados durante los últimos cinco años, principalmente en la zona norte del país, ha generado un mayor interés por esta enfermedad. Esta guía fue elaborada con la intención de establecer un consenso para el diagnóstico, tratamiento y seguimiento de los pacientes con enfermedad de Fabry, basado en la evidencia científica, actualmente disponible.


Subject(s)
Humans , Fabry Disease/diagnosis , Fabry Disease/therapy , Chile , Consensus , Diagnosis, Differential , Enzyme Replacement Therapy , Fabry Disease/complications , Genetic Counseling , Isoenzymes/administration & dosage , alpha-Galactosidase/administration & dosage
14.
Arq. bras. oftalmol ; 74(6): 447-448, nov.-dez. 2011. ilus
Article in English | LILACS | ID: lil-613448

ABSTRACT

Fabry disease is an X-linked disease of glycosphingolipid (GL) metabolism. The accumulation of GL in tissues can affect multiple organ systems. Initial symptoms includes episodes of severe pain in the extremities, cornea verticillata and skin lesions. In late stages, kidney, heart and brain can be involved. This report attempts for importance of cornea verticillata in the diagnosis of Fabry disease in a young patient with pain in the lower limb extremities.


A doença de Fabry é um erro inato no metabolismo de glicosfingolipides (GL) ligado ao cromossomo X. O acúmulo de GL nos tecidos pode afetar múltiplos órgãos e sistemas. Os sintomas iniciais incluem episódios de dor nas extremidades, córnea verticilata e lesões na pele. Em estágios avançados, os rins, coração e cérebro podem ser envolvidos. Este relato de caso enfatiza para importância da córnea verticilata para o diagnóstico de doença de Fabry em paciente jovem com dor nos membros inferiores.


Subject(s)
Adolescent , Humans , Male , Fabry Disease/diagnosis , alpha-Galactosidase/blood , Biomarkers/blood , Corneal Opacity/complications , Corneal Opacity/diagnosis , Fabry Disease/genetics
15.
Article in English | WPRIM | ID: wpr-31546

ABSTRACT

Fabry's disease is an X-linked lysosomal storage disorder caused by abnormalities in the alpha-galactosidase A (GLA) gene, which leads to a GLA deficiency and to the intracellular deposition of globotriaosylceramide (Gb3) within vascular endothelium and other tissues. It manifests as progressive multiple organ dysfunctions caused by the deposition of Gb3. On the other hand, congenital agammaglobulinemia is usually caused by mutations in Bruton's tyrosine kinase (Btk) gene with X-linked dominence, suppresses B cell maturation, and causes recurrent pyogenic infections. In former reports, the distance between the loci in the Xq22 region of the human X chromosome was found to be about 69 kilobases. A 23-yr-old man diagnosed with congenital agammaglobulinemia at age 5, showed typical clinical and laboratory and histopathological findings of Fabry's disease. The genetic basis of this combination of the two syndromes was studied in this patient. Here, we report a case of Fabry's disease with congenital agammaglobulinemia.


Subject(s)
Adult , Agammaglobulinemia/congenital , Chromosomes, Human, X , Fabry Disease/diagnosis , Humans , Kidney/pathology , Male , Microscopy, Electron , Sequence Analysis, DNA , Skin/pathology , alpha-Galactosidase/genetics
16.
Rev. bras. neurol ; 46(1)jan.-mar. 2010. ilus, tab
Article in Portuguese | LILACS | ID: lil-553536

ABSTRACT

A doença de Anderson-Fabry é uma desordem de acúmulo lisossomial causada por deficiência da enzima alfa-galactosidase A (@-Gal A), relacionada com mutação recessiva no cromossomo X, resultando em acúmulo de glicolípides nas células endoteliais, nas células musculares lisas, nas células periteliais vasculares, e, variavelmente, nos neurônios e células ganglionares. O quadro clínico inicia-se na adolescência, com dores intensas e recorrentes nas extremidades, seguidas por angioceratomas, distrofia corneana, insuficiência renal e comprometimento cardíaco. Pacientes com dosagem de ?-Gal A extremamente baixa tendem a evoluir para óbito ao redor dos 40 anos de idade devido à insuficiência renal, infarto do miocárdio ou acidente vascular cerebral. Comprometimento isolado ou do coração ou do rim está relacionado com dosagem ao redor de 1 a 10% da @-Gal A. Descrevemos um paciente de 63 anos, masculino, apresentando, exclusivamente, acroparestesia dolorosa crônica e intensa, com dosagem não detectável de @-Gal A e comprometimento exclusivo de nervos periféricos, principalmente de fibras finas. Biópsia de pele mostrou ausência de nervos intraepidérmicos. A Doença de Fabry com neuropatia exclusiva é uma variante ainda não descrita.


Anderson-Fabry disease is a lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase (@-Gal A) related to recessive mutation carried on the X chromosome, resulting in glicolipid accumulation in the cytoplasm of endothelial cells, smooth muscle cells, and perithelial cells of blood vessels, and variably in neurons and ganglionic cells. Clinical onset of the disease occurs during adolescence with recurrent episodes of severe pain in the extremities, followed by angiokeratomas, cornea dystrophy, renal insufficiency and cardiac involvement. Patients that have extremely low @-Gal A activity are likely to evolve to death at about 40 years of age due to renal failure, heart attack or brain stroke. We present a 63 year-old man, showing exclusively chronic and severe painful acroparesthesia, with undetectable @-Gal A and exclusive involvement of peripheral nerves, mainly thin fibers. Skin biopsy showed no intraepidermal nerve fibers. Fabry disease manifested with exclusive peripheral neuropathy is a variant not yet described.


Subject(s)
Humans , Male , Middle Aged , Biopsy , Fabry Disease/diagnosis , Peripheral Nervous System Diseases/diagnosis
17.
Medicina (B.Aires) ; 70(1): 37-43, feb. 2010. ilus, tab
Article in Spanish | LILACS | ID: lil-633715

ABSTRACT

La enfermedad de Fabry es un desorden lisosomal de transmisión ligada al cromosoma X debida al déficit de la enzima alfa galactosidasa A, con acumulación multisistémica de globotriaosilceramida y compromiso neurológico, gastrointestinal, cardíaco, renal, dermatológico y oftalmológico. Estudios recientes indican que las mujeres heterocigotas desarrollan síntomas similares a los de los varones, pero no existen en nuestro país datos comparativos respecto de la frecuencia relativa de manifestaciones clínicas, edad de inicio y gravedad entre hombres y mujeres con enfermedad de Fabry. Identificamos 59 pacientes adultos sintomáticos con enfermedad de Fabry: 32 varones (edad media: 34.8 años) y 27 mujeres (edad media: 46.6 años). El diagnóstico se hizo por estudios enzimáticos en los hombres y genéticos en las mujeres. Se evaluó la frecuencia y la gravedad de las manifestaciones de la enfermedad. Las manifestaciones más frecuentes fueron acroparestesias, angioqueratomas, hipohidrosis y córnea verticilada; las tres primeras fueron estadísticamente más frecuentes en hombres, en los cuales la gravedad de estos síntomas fue significativamente mayor. Proteinuria e hipertrofia ventricular izquierda fueron hallazgos frecuentes tanto en hombres como en mujeres. Hubo una latencia prolongada entre la edad del inicio y la del diagnóstico de 14 años para varones y 30 para mujeres. La enfermedad de Fabry es una enfermedad subdiagnosticada y potencialmente letal que afecta a ambos sexos. La existencia de reemplazo enzimático obliga a identificar precozmente los síntomas y signos sugestivos de la enfermedad para realizar un diagnóstico y tratamiento precoces.


Fabry disease is an X- linked lysosomal disorder due to deficient activity of the enzyme alpha galactosidase A which leads to multisystemic storage of globotriaosylceramide with neurologic, gastrointestinal, cardiac, renal, skin and ophtalmological involvement. Recent studies indicate that heterozygous females develop symptoms similar to the males, but comparative information regarding the relative frequency of clinical manifestations, age of onset and severity of the disorder between males and females with Fabry disease is not available in Argentina. We identified 59 symptomatic adult patients with Fabry disease: 32 males (mean age 34.8 years) and 27 females (mean age 46.6 years). Diagnosis was made by enzymatic analysis in males and by genetic studies in females. We compared the frequency and severity of the clinical manifestations in females and males with this disease. The most frequent manifestations were: acroparesthesias, angiokeratomas, hypohydrosis (all them were significantly more frequent in males than in females, as well as the severity of symptoms), and cornea verticillata. Proteinuria and ventricular hypertrophy were frequent findings both in males and females. There was a delayed latency between age at onset and age at diagnosis in our group: 14 years for men and 30 years for females. Fabry disease is an underdiagnosed and potentially fatal disorder that affects both sexes. The availability of enzyme replacement therapy should stimulate the identification of signs and symptoms suggestive of this disorder, to allow earlier diagnosis and treatment.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Fabry Disease/diagnosis , alpha-Galactosidase/genetics , Argentina , Severity of Illness Index , Sex Factors , Fabry Disease/complications , Hypertrophy, Left Ventricular/diagnosis , alpha-Galactosidase/blood , Corneal Opacity/diagnosis , Corneal Opacity/etiology , Heterozygote , Angiokeratoma/diagnosis , Angiokeratoma/etiology , Mutation
19.
An. bras. dermatol ; 84(4): 367-376, jul.-ago. 2009. ilus, tab
Article in Portuguese | LILACS | ID: lil-529082

ABSTRACT

A doença de Fabry é enfermidade de armazenamento lisossômico rara, ligada ao cromossomo-X, causada pela deficiência parcial ou completa da enzima alfagalactosidase A. O defeito resulta no acúmulo de globotriaosilceramida no endotélio vascular e tecidos viscerais, sendo a pele, o coração, os rins e o sistema nervoso central os mais afetados. As autoras realizam revisão da literatura relacionada a essa afecção e ressaltam que o reconhecimento precoce dos angioqueratomas e da hipoidrose constitui sinal-chave no diagnóstico dessa doença grave. Destacam também a necessidade de esses doentes serem avaliados por equipe multidisciplinar.


Fabry disease is an uncommon, X-linked lysosomal storage disorder, caused by partial or complete deficiency of the enzyme a-galactosidase A. The defect leads to accumulation of uncleaved globotriaosylceramide on the vascular endothelium and visceral tissues, being the skin, heart, kidneys and central nervous system the most affected organs. We performed review of the literature related to the disease and emphasized that early recognition of angiokeratomas and hypohidrosis are key diagnostic signs of this serious disease. We also addressed the need of multidisciplinary assessment of these patients.


Subject(s)
Humans , Fabry Disease , Fabry Disease/complications , Fabry Disease/diagnosis , Skin Diseases/etiology
20.
Article in English | IMSEAR | ID: sea-139032

ABSTRACT

Fabry disease is a lysosomal storage disease with an X-linked inheritance pattern, which presents in childhood as acroparaesthesias. Its non-specific symptoms often lead to delays in the diagnosis. We report the case of a 13-year-old boy who presented with typical acroparaesthesia of Fabry disease, his younger brother had gastrointestinal manifestations of the disease and their mother’s symptoms suggested that she is a carrier. Enzyme replacement therapy helped in ameliorating the patient’s symptoms and preventing complications such as renal failure, stroke and cardiovascular disorders.


Subject(s)
Adolescent , Fabry Disease/diagnosis , Fabry Disease/drug therapy , Fabry Disease/genetics , Humans , Isoenzymes/therapeutic use , Lysosomal Storage Diseases/diagnosis , Lysosomal Storage Diseases/drug therapy , Lysosomal Storage Diseases/genetics , Recombinant Proteins/therapeutic use , Male , Risk Factors , alpha-Galactosidase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL